HIV in the intensive care unit

Infectious Diseases in Critical Care

Volumn , Issue , 2007, Pages 51-64

  Rebollo, P Castro ^a   Nicolas J M ^a   Gatell, J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892107922     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-34406-3_6     Document Type: Chapter

References (68)

1. UNAIDS/WHO (2005) AIDS epidemic update: December 2005. http://www.unaids.org
2. Morris A, Masur H, Huang L (2006) Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 34:42-49
3. Wachter RM, Luce JM, Turner J, et al. (1986) Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. AmRev Respir Dis 134:891-896
4. Wachter RM, Luce JM, Safrin S, et al. (1995) Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA 273:230-235
5. Gallant JE, Chaisson RE, Moore RD (1998) The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia onmortality and subsequent complications. Chest 114:1258-1263
6. Rogers PL, Lane HC, Henderson DK, et al. (1989) Admission of AIDS patients to a medical intensive care unit: causes and outcome. Crit Care Med 17:113-117
7. De Palo VA, Millstein BH, Mayo PH, et al. (1995) Outcome of intensive care in patients with HIV infection. Chest 107:506-510
8. Lazard T, Retel O, Guidet B, et al. (1996) AIDS in a medical intensive care unit: immediate prognosis and long-term survival. JAMA 276:1240-1245
9. Rosen MJ, Clayton K, Schneider RF, et al. (1997) Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 155:67-71
10. Nickas G, Wachter RM (2000) Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 160:541-547
11. Rosenberg AL, Seneff MG, Atiyeh L, et al. (2001) The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 29:548-556
12. Leifeld L, Rockstroh J, Skaide S, et al. (2000) Indication, outcome and follow up of intensive care in patients with HIV-infection. Eur J Med Res 5:199-202
13. Paul S, Gilbert HM, Ziecheck W, et al. (1999) The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 13:415-418
14. Palella FJ, Jr, Delaney KM, Moorman AC, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl JMed 338:853-860
15. Kaplan JE, Hanson D, Dworkin MS, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 Suppl 1:S5-14
16. Nuesch R, Geigy N, Schaedler E, Battegay M (2002) Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 21:684-687
17. Khouli H, Afrasiabi A, Shibli M, et al. (2005) Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 20:279-285
18. Afessa B, Green B (2000) Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 118:138-145
19. Vincent B, Timsit JF, Auburtin M, et al. (2004) Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 30:859-866
20. Morris A, Creasman J, Turner J, et al. (2002) Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. AmJ Respir Crit Care Med 166:262-267
21. Narasimhan M, Posner AJ, De Palo VA, et al. (2004) Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 125:1800-1804
22. Castilla J, Sobrino P, De La FL, et al. (2002) Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 16:1945-1951
23. Hamers FF, Downs AM (2004) The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 364:83-94
24. Casalino E, Wolff M, Ravaud P, et al. (2004) Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 18:1429-1433
25. Morris A, Wachter RM, Luce J, et al. (2003) Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 17:73-80
26. Alves C, Nicolas JM, Miro JM, et al. (2001) Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. Eur Respir J 17:87-93
27. Miro JM, Laguno M, Moreno A, et al. The Hospital Clinic OLT in HIV Working Group (2006) Management of end stage liver disease (ESLD): What is the current role of orthotopic liver transplantation (OLT) ? J Hepatol 44 Suppl 1:S140-S145
28. Wachter RM, Russi MB, Bloch DA, et al. (1991) Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis 143:251-256
29. Bedos JP, Dumoulin JL, Gachot B, et al. (1999) Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. Crit Care Med 27:1109-1115
30. Casalino E, Mendoza-Sassi G, Wolff M, et al. (1998) Predictors of short-and long-term survival in HIV-infected patients admitted to the ICU. Chest 113:421-429
31. Masur H (2002) Acquired immunodeficiency syndrome in the intensive care unit: will human immunodeficiency virusrelated admissions continue to decline? Am J Respir Crit Care Med 166:258-259
32. Anonymous (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1-19
33. Benson CA, Kaplan JE, Masur H, et al. (2004) Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 53:1-112
34. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. (1999) Effects ofmutations in Pneumocystis carinii dihydropteroate synthase gene onoutcome of AIDS-associatedP. carinii pneumonia. Lancet 354:1347-1351
35. Kovacs JA, Gill VJ, Meshnick S, et al. (2001) New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 286:2450-2460
36. Baldanti F, Paolucci S, Parisi A, et al. (2002) Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy. Clin Infect Dis 34:1146-1149
37. Kinloch-de Loes S, de Saussure P, Saurat JH, et al. (1993) Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis 17:59-65
38. Huang ST, Lee HC, Liu KH, et al. (2005) Acute human immunodeficiency virus infection. J Microbiol Immunol Infect 38:65-68
39. Bartlett JG, Lane HC, Panel on Clinical Practices for Treatment of HIV Infection convened by the DHHS (2005) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSinfo.nih.gov
40. Falco V, Rodriguez D, Ribera E, et al. (2002) Severe nucleoside- associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34:838-846
41. Martinez E, Blanco JL, Arnaiz JA, et al (2001) Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15:1261-1268
42. Lonergan JT, Behling C, Pfander H, et al. (2000) Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31:162-166
43. Miller KD, Cameron M, Wood LV, et al. (2000) Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133:192-196
44. Hewitt RG (2002) Abacavir hypersensitivity reaction. Clin Infect Dis 34:1137-1142
45. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15:1843-1848
46. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423-1430
47. Bonnet F, Bonarek M, Morlat P, et al. (2003) Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 36:1324-1328
48. Claessens YE, Chiche JD, Mira JP, et al. (2003) Bench-tobedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care 7:226-232
49. Bozzette SA, Ake CF, Tam HK, et al. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702-710
50. Friis-Moller N, Sabin CA, Weber R, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003
51. Holmberg SD, Moorman AC, Williamson JM, et al. (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747-1748
52. Martinez E, Domingo P, Galindo MJ, et al. (2004) Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 38:1017-1023
53. Martinez E, Casamitjana R, Conget I, et al. (1998) Protease inhibitor-associated hyperinsulinaemia. AIDS 12:2077-2079
54. Martinez E, Gatell J (1998) Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 352:821-822
55. Shelburne SA, III, Hamill RJ, Rodriguez-Barradas MC, et al. (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81:213-227
56. Cheng VC, Yuen KY, Chan WM, et al. (2000) Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30:882-892
57. Wislez M, Bergot E, Antoine M, et al. (2001) Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 164:847-851
58. Piscitelli SC, Gallicano KD (2001) Interactions among drugs for HIV and opportunistic infections. N Engl J Med 344:984-996
59. Kotb R, Vincent I, Dulioust A, et al. (2006) Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol
60. Fantoni M, Autore C, Del Borgo C (2001) Drugs and cardiotoxicity in HIV and AIDS. AnnNYAcad Sci 946:179-199
61. Soni N, Pozniak A (2001) Continuing HIV therapy in the ICU. Crit Care 5:247-248
62. Foudraine NA, Weverling GJ, van Gool T, et al. (1998) Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 12:35-41
63. Murdaca G, Campelli A, Setti M, et al. (2002) Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS 16:304-305
64. Tantisiriwat W, Tebas P, Clifford DB, et al. (1999) Progressivemultifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28:1152-1154
65. Mackie NE, Fidler S, Tamm N, et al. (2004) Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 5:180-184
66. Sellier P, Clevenbergh P, Mazeron MC, et al. (2004) Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. Scand J Infect Dis 36:533-535
67. Kilby JM, Goepfert PA, Miller AP, et al. (2000) Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med 133:435-438
68. Zavascki AP (2005) Severe acute hepatitis due to retroviral rebound syndrome after discontinuation of highly active antiretroviral therapy. J Infect (in press)